With over a decade of experience synthesizing DNA, Azenta Life Sciences, formerly GENEWIZ has developed a unique adeno-associated virus (AAV) plasmid synthesis service, the first of its kind on the market. This service provides researchers working with adeno-associated virus vectors with synthesis and cloning of transgene expression cassettes into custom AAV vectors with high efficiencies. Azenta’s AAV plasmid synthesis service comes bundled with our new AAV plasmid preparation protocol to deliver mini- to giga-scale AAV plasmids that have been sequence-verified by our AAV-ITR Sanger sequencing service.
We understand the importance of intact inverted terminal repeat (ITR) regions in downstream AAV gene therapy applications, as seen in recent publications, therefore Azenta maintains a 2-step QC process and ITR correction by gene synthesis to ensure the integrity of your ITR regions.
Extensive experience working with a wide variety of custom AAV vectors with ITR synthesis capability
FREE codon optimization tools based on an advanced algorithm for high protein expression
Ensure intact ITR regions before and after cloning with our robust 2-step QC system including sequence verification using Azenta’s proprietary AAV-ITR sequencing and ITR correction via gene synthesis
Mini- to giga-scale preps using proprietary AAV plasmid preparation protocol
Original AAV inverted terminal repeat shows a deletion mutation. Regular PCR amplification cannot repair the sequence due to its repetitive nature. Azenta can successfully deliver repaired inverted terminal repeat regions through specific ITR correction technique.
Each inverted terminal repeat region is important in downstream AAV gene therapy applications*
|Residue of Non-Recombinant AAV (r(AAV)) Encapsided DNA||A-A’|
|Packing||A-A’ (trs), D|
|Encapsidation||A-A’, B-B’, C-C’, D|
|Affinity to Rep Protein||A-A’, B-B’, C-C’|
|Rescue||A-A’ (trs), D|
|Integration||A-A’ (trs), D|
* Savy, A., Dickx, Y., Nauwynck, L., Bonnin, D., Merten, O.W. and Galibert, L., 2017. Impact of inverted terminal repeat integrity on rAAV8 production using the baculovirus/Sf9 cells system. Human Gene Therapy Methods, 28(5), pp.277-289.
*Zhou, Q., Tian, W., Liu, C., Lian, Z., Dong, X. and Wu, X., 2017. Deletion of the B-B’and C-C’regions of inverted terminal repeats reduces rAAV productivity but increases transgene expression. Scientific reports, 7(1), pp.1-13.
*Maurer, A.C. and Weitzman, M.D., 2020. Adeno-Associated Virus Genome Interactions Important for Vector Production and Transduction. Human Gene Therapy, 31(9-10), pp.499-511.
*trs – terminal resolution site
Working with AAV vectors can be challenging. In this on-demand workshop & roundtable discussion, you’ll gain a better understanding of the AAV development pipeline for gene therapy research and learn how to optimize upstream and downstream processes including AAV synthesis, sequencing, bioinformatics, and storage.
Learn how Azenta can further support your AAV gene therapy research